Skip to main content
Equibles
NSPR logo

NSPR · InspireMD, Inc. · Metrics

Track NSPR — free

Use NSPR with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research NSPR.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.47 +0.01 (+2.86%) At close · Oct 28 Q2 2026 earnings call transcript
Rebalance outlook locked
Going-concern doubt — flagged Aug 14, 2026

Substantial doubt about the company's ability to continue as a going concern.

“Management has concluded that there is substantial doubt about our ability to continue as a going concern, and our condensed financial statements for the quarter ended June 30, 2026 includes an explanatory paragraph as to our ability to continue as a going concern, which could prevent us from obtaining new financing on reasonable terms or at all.”
View the 10-Q filed Aug 14, 2026
Market Cap
$21.15M
Shares
46.49M
Volume · Oct 28 524.8K Avg daily vol (3M) 128.46K

NSPR metrics

79 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$0.47
Market cap
$21.15M

Price action

20 metrics
Price change (1W)
+3.8%
Price change (30D)
-34.0%
Price change (3M)
-33.1%
Price change (6M)
-60.1%
Price change (YTD)
-74.4%
Price change (1Y)
-79.9%
Trailing year
Price change (5Y)
-88.5%
52-week high
$2.29
52-week low
$0.44
Change from 52-week high
-80.1%
Change from 52-week low
+3.8%
Annualized volatility
65.0%
Annualized volatility (3M)
72.0%
Beta
1.0
RSI (14D)
28.7
Price vs SMA 50
-34.1%
Price vs SMA 200
-58.2%
Avg volume (3M)
121,102
Relative volume
3.2
Average dollar volume
$77,396

Company

3 metrics
Sector
Healthcare
Industry
Medical Devices
Shares outstanding
46.49M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
-0.9×
EV / EBITDA
—
EV / EBIT
—
P / sales
1.9×
reciprocal yield 51.8%
P / book
0.7
reciprocal yield 150.6%
FCF yield
-203.0%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-250.9%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
4.6×
reciprocal yield 21.8%
EV / revenue historical average (5Y)
3.8×
reciprocal yield 26.3%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-17

Profitability

9 metrics
Gross margin
18.1%
Operating margin
-494.0%
Trailing 12 months
Net margin
-484.1%
Gross profit (TTM)
$1.96M
Operating profit (TTM)
−$53.56M
Net income (TTM)
−$52.48M
Trailing 12 months
Diluted EPS (TTM)
$-1.05
FCF margin
-391.7%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
$-135.17
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$1.27

Growth

11 metrics
Revenue growth YoY
-0.4%
Year over year
Net income growth YoY
—
Revenue (TTM)
$10.84M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+66.0%
Year over year · more shares
Revenue CAGR (3Y)
+20.2%
Revenue CAGR (5Y)
+29.3%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-166.6%
Return on assets
-117.6%
Debt / equity
0.0
Current ratio
3.8
EBITDA (TTM)
−$9.66M
Free cash flow (TTM)
−$42.46M
Quick ratio
3.5
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$30.42M
Latest balance sheet
Cash & equivalents
$15.15M
Total assets
$44.64M
Total debt
$0

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$41.21M
Capital expenditures (TTM)
$1.25M
R&D (TTM)
$16.17M
SG&A (TTM)
—
Stock compensation (TTM)
$10.71M
R&D / revenue
149.1%
Stock compensation / revenue
98.8%

Ownership (13F)

9 metrics
13F filers
38
13F filer change QoQ
+3
Institutional ownership
46.3%
Conviction holders (share of 13F filers)
0.0%
Crowding (high-turnover and private-fund holders)
28.5%
Private-fund adviser ownership
26.1%
Active holders' share change QoQ
-9.1%
Holder tenure
10.0
Price vs estimated holder cost
-66.8%

Ownership (registered funds)

1 metrics
Index-fund ownership
0.3%

Short interest

3 metrics
Short interest
0.2%
Latest settlement · 1.0 days to cover
Days to cover
1.0d
Short-squeeze score
50 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1433607 CUSIP 45779A846 13F (30d) 6 filings 6 filers Visit website Investor relations